Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 26, 2014
- Accepted in final form July 27, 2015
- First Published January 6, 2016.
Article Versions
- Previous version (January 6, 2016 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Tina Roostaei, MD, MPH*,
- Shokufeh Sadaghiani, MD*,
- Min Tae M. Park, BSc,
- Rahil Mashhadi, MSc,
- Aria Nazeri, MD,
- Sina Noshad, MD, MPH,
- Mohammad Javad Salehi, MSc,
- Maryam Naghibzadeh, MD,
- Abdorreza Naser Moghadasi, MD,
- Mahsa Owji, MD,
- Rozita Doosti, MD,
- Amir Pejman Hashemi Taheri, MD,
- Ali Shakouri Rad, MD,
- Amirreza Azimi, MD,
- M. Mallar Chakravarty, PhD,
- Aristotle N. Voineskos, MD, PhD, FRCP(C),
- Arash Nazeri, MD and
- Mohammad Ali Sahraian, MD
- Tina Roostaei, MD, MPH*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Alzheimer Society of Canada
NONE
NONE
NONE
NONE
NONE
NONE
- Shokufeh Sadaghiani, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Min Tae M. Park, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rahil Mashhadi, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aria Nazeri, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sina Noshad, MD, MPH,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mohammad Javad Salehi, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maryam Naghibzadeh, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Abdorreza Naser Moghadasi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mahsa Owji, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rozita Doosti, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Amir Pejman Hashemi Taheri, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ali Shakouri Rad, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Amirreza Azimi, MD,
NONE
NONE
NONE
international journal of neurology research
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- M. Mallar Chakravarty, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aristotle N. Voineskos, MD, PhD, FRCP(C),
NONE
NONE
NONE
(1) Schizophrenia Bulletin, Editorial board member, 2015.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) CIHR, Principal Investigator, 2013-2018, (2) CIHR, Supervisor, 2013-2016, (3) NIMH, R01MH099167, Principal Investigator, 2012-2017, (4) NIMH, R01MH102324, Principal Investigator, 2014-2019, (5) OMHF, New Investigator Fellowship, 2012-2015
NONE
(1) Centre for Addiction and Mental Health (CAMH) Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Arash Nazeri, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Centre for Addiction and Mental Health (CAMH) Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Mohammad Ali Sahraian, MD
1.Middle east Merck Sereno 2.Cinnagen Company 3.Novartis Iran
NONE
1.Cinnagen Company, Travel grant 2.Novartis, Travel grant 3.Merck Sereno, Speaker honoraria and travel grant
1.Iranian Journal of Neurology, Section editor for Multiple Sclerosis, 2012-now
NONE
NONE
NONE
1.Cinnagen Company 2.Merck Sereno 3.Novartis 4.Biogen Idec 5.Bayer-schering
1.Cinnagen Company 2.Merck Sereno 3.Novartis 4.Biogen Idec 5.Bayer-schering
NONE
NONE
1.Iranian MS society 2.Cinnagen Company 3.Osveh Pharma 4.Merck Sereno
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the MS Research Center, Neuroscience Institute (T.R., S.S., Aria Nazeri, S.N., M.N., A.N.M., M.O., R.D., A.A., Arash Nazeri, M.A.S.), Interdisciplinary Neuroscience Research Program (T.R., S.S., M.N., Arash Nazeri), Urology Research Center (R.M.), Department of Neurology (A.N.M., M.A.S.), and Department of Radiology (A.P.H.T., A.S.R.), Tehran University of Medical Sciences, Iran; Kimel Family Translational Imaging-Genetics Laboratory (T.R., A.N.V., Arash Nazeri), Research Imaging Centre, Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Toronto; Department of Psychiatry (T.R., A.N.V., Arash Nazeri), University of Toronto; Cerebral Imaging Centre (M.T.M.P., M.M.C.), Douglas Mental Health Institute, Verdun; Schulich School of Medicine and Dentistry (M.T.M.P.), Western University, London, Canada; Department of Electrical Engineering (M.J.S.), Sharif University of Technology, Tehran, Iran; Department of Neurology (A.A.), Thomas Jefferson University, Philadelphia, PA; and Departments of Psychiatry and Biomedical Engineering (M.M.C.), McGill University, Montreal, Canada.
- Correspondence to Dr. Sahraian: msahrai{at}tums.ac.ir or Dr. Nazeri: arashnazeri{at}gmail.com
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
The Multiple Sclerosis Functional CompositeA clinically meaningful measure of disabilityChris H. Polman, Richard A. Rudick et al.Neurology, April 26, 2010 -
Article
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGavin Giovannoni, Jeffrey A. Cohen, Alasdair J. Coles et al.Neurology, October 12, 2016 -
Articles
Comparisons of patient self-report, neurologic examination, and functional impairment in MSE.L.J. Hoogervorst, L.M.L. van Winsen, M.J. Eikelenboom et al.Neurology, April 10, 2001 -
Article
Network Damage Predicts Clinical Worsening in Multiple SclerosisA 6.4-Year StudyMaria A. Rocca, Paola Valsasina, Alessandro Meani et al.Neurology: Neuroimmunology & Neuroinflammation, May 21, 2021